NCT04731155

Impact of Early PCSK9 Inhibitor on Heart After Acute Myocardium Infarction

Impact of Early PCSK9 Inhibitor on Heart After Acute Myocardium

• Status: Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Shanghai Tong Ren Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This is a prospect, multi-center, random study to investigate whether early offering PCSK9 inhibitor to acute myocardium infarction(AMI) can alleviate ventricular remodeling after primary percutaneous intervention(PPCI). Totally,twenty acute myocardium infarction subjects will be enrolled in this study after consent information. After randomization, the control group will receive standard therapy for AMI including PPCI. The experiment group will receive first PCSK9 inhibitor before PPCI, then twice a month until 3 months later. Six month after AMI, Myocardial salvage index will be used to evaluate ventricular remodeling. TnI peaking time and LDL control rates also will be recorded and compared.

Conditions

• Early PCSK9 Inhibitor on Ventricular Remodling

Interventions

Type	Name	Description
DRUG	PCSK9 inhibitor （Alirocumab）plus standard medications	PCSK9 inhibitor（Alirocumab） was giving to subjects before PPCI and continued twice a month until 3 month after AMI
DRUG	standard medications	standard medications was giving to subjects according guidelines

Timeline

• Start date: 2021-04-12
• Primary completion: 2025-10-01
• Completion: 2025-10-01
• First posted: 2021-01-29
• Last updated: 2025-05-21

Locations

2 sites across 1 country: China